The median overall survival in multiple myeloma is rapidly approaching 10 years; however, nearly a fifth of patients the prognosis remains poor. Therefore, modern-day management should be individualized, with more intense and continuous approach these high-risk patients. This includes first-line treatment based on multi-drug combinations employing most effective drug combinations, upfront autol...

Cytogenetic abnormalities (CAs) such as t(4;14), t(14;16) or del(17p), and nonhyperdiploidy are associated with poor prognosis in multiple myeloma. We evaluated the influence of CAs by FISH and DNA ploidy by flow cytometry on response and survival in 232 elderly, newly diagnosed multiple myeloma patients receiving an induction with weekly bortezomib followed by maintenance therapy with bortezom...